NVAX Q1 2023 Earnings — Novavax, Inc. Revenue & Financial Results | Market Cap Arena

NVAXNovavax, Inc.

$2B

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

-$6M-101.1% YoY

Gross Profit

-$41M630.3% margin

Operating Income

-$313M4865.7% margin

Net Income

-$294M4572.3% margin

EPS (Diluted)

$-3.41

QoQ Revenue Growth

-102.2%

Cash Flow

Operating Cash Flow

-$326M

Free Cash Flow

-$349M

Stock-Based Comp.

$29M

Balance Sheet

Total Assets

$1.5B

Total Liabilities

$2.4B

Stockholders' Equity

-$896M

Cash & Equivalents

$625M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	-$6M	$605M	-101.1%
Gross Profit	-$41M	$589M	-106.9%
Operating Income	-$313M	$209M	-249.4%
Net Income	-$294M	$203M	-244.5%

Revenue Segments

Grant

$87M108%

Royalties and Other

$1M1%

Product

-$7M-9%

Geographic Segments

Europe

$57M

Rest of the World

-$65M